GlassScriptPhysician profile
Kira Macdougall
NPI 1770072001
$3,328.24
in general payments reported to CMS, 2019-2025
35 companies · $1,214 in 2025
The $1,214 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $262 · 2022: $373 · 2023: $548 · 2024: $932 · 2025: $1,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,432 · Education: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,431.51 |
| Education | $261.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $607.12 | 2021-2025 | Calquence, Imfinzi, Enhertu |
| Seagen INC. | $298.94 | 2022-2023 | |
| Exelixis INC. | $176.59 | 2024-2025 | Cabometyx |
| Secura Bio, INC. | $170.18 | 2023 | Copiktra |
| Takeda Pharmaceuticals U.S.A., INC. | $163.93 | 2024-2025 | Alunbrig, Fruzaqla, Ninlaro |
| Aveo Pharmaceuticals, INC. | $160.94 | 2022-2024 | |
| Astellas Pharma US INC | $156.99 | 2021-2023 | |
| Incyte Corporation | $148.83 | 2022-2025 | Monjuvi, Pemazyre, Zynyz |
| Janssen Biotech, INC. | $144.69 | 2024-2025 | Rybrevant, Erleada, Darzalex |
| Mallinckrodt Hospital Products INC. | $144.35 | 2024 | Uvadex |
| Novocure INC. | $130.79 | 2025 | Optune Gio |
| Adc Therapeutics America, INC. | $116.15 | 2023 | |
| Novartis Pharmaceuticals Corporation | $110.93 | 2024-2025 | |
| Genzyme Corporation | $86.69 | 2024-2025 | |
| Gilead Sciences, INC. | $85.78 | 2025 | Trodelvy |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $73.10 | 2025 | Yescarta |
| Bayer Healthcare Pharmaceuticals INC. | $61.75 | 2024-2025 | |
| Array Biopharma INC | $56.54 | 2024-2025 | Braftovi, Tukysa, Mektovi |
| Blueprint Medicines Corporation | $55.76 | 2024-2025 | Ayvakit |
| Beigene USA, INC. | $38.79 | 2024-2025 | Tevimbra |
| Sobi, INC | $31.33 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $30.55 | 2025 | Libtayo |
| Iovance Biotherapeutics, INC. | $30.08 | 2025 | Amtagvi |
| Daiichi Sankyo INC. | $30.02 | 2024-2025 | Enhertu |
| Abbvie INC. | $27.80 | 2025 | |
| Alexion Pharmaceuticals, INC. | $23.82 | 2024 | Ultomiris |
| Merck Sharp & Dohme LLC | $22.65 | 2024 | Keytruda |
| Pharmaessentia USA Corporation | $22.12 | 2025 | Besremi |
| Legend Biotech USA INC. | $20.80 | 2025 | Carvykti |
| Genmab U.S., INC. | $20.24 | 2024 | Epkinly |
| Eisai INC. | $17.73 | 2025 | |
| Emd Serono, INC. | $16.99 | 2024 | |
| Karyopharm Therapeutics INC. | $15.53 | 2025 | Xpovio |
| Glaxosmithkline, LLC. | $15.47 | 2024 | Ojjaara |
| Ipsen Biopharmaceuticals, INC | $14.27 | 2025 | Onivyde |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kira Macdougall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.